Incyte to present six oncology studies at ESMO Congress 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
July 17, 2026 1:10 PM EDTRapid oral presentations will highlight new Phase 1 data across Incytes solid tumor portfolio Both INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq: INCY) today announced that it will highlight data from several programs in its oncology portfolio... More
